- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Playback speed
10 seconds
HER2 Ultra-Low: Is It Real? A Close Look at Companion Diagnostics for Trastuzumab Deruxtecan (T-DXd) in Breast Cancer
By
Yale Cancer Center
FEATURING
David Rimm
By
Yale Cancer Center
FEATURING
David Rimm
83 views
October 25, 2024
Comments 0
Login to view comments.
Click here to Login
Breast